The US Food and Drug Administration conducted a routine cGMP inspection of a facility belonging to OneSource Specialty Pharma Limited.
1 report, 1 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The US Food and Drug Administration conducted a routine cGMP inspection of a facility belonging to OneSource Specialty Pharma Limited.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- USFDA conducted an inspection of Strides Pharma Science Limited's flagship manufacturing facility in Bengaluru, India.Sub-event
USFDA inspected OneSource Specialty Pharma facility in Bengaluru.1 source
Keep exploring
The entities involved
-
United States Food and Drug Administration
agency of the US Department of Health and Human Services
-
Bengaluru
capital city of Karnataka state in India
Related events
- Routine cGMP inspection found three observations at a Strides Pharma Science Limited manufacturing facility in Chennai.
- The US Food and Drug Administration conducted a cGMP inspection at a facility belonging to Cipla.
- A routine inspection of a GMP manufacturing unit in Visakhapatnam, Andhra Pradesh, was conducted by the United States Food and Drug Administration and confirmed regulatory compliance.